Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib, Paclitaxel, Carboplatin, and Radiation for Stage IIIA/IIIB NSCLC
NCT00093756Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Jan 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Sep 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00093756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093756.